{
    "id": 7522,
    "fullName": "AR W742C",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "AR W742C (also referred to as W741C) lies within the ligand-binding domain of the Ar protein (PMID: 16266977). W742C results in relaxation of Ar ligand-specificity, and the ability to be aberrantly activated by the anti-androgen, bicalutamide, in cell culture (PMID: 16266977, PMID: 26760770).",
            "references": [
                {
                    "id": 3011,
                    "pubMedId": 16266977,
                    "title": "Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16266977"
                },
                {
                    "id": 11247,
                    "pubMedId": 26760770,
                    "title": "BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26760770"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "W742C",
    "createDate": "06/11/2015",
    "updateDate": "12/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 146272,
        "transcript": "NM_000044",
        "gDna": "chrX:g.67717530G>T",
        "cDna": "c.2226G>T",
        "protein": "p.W742C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2381,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR W741C conferred resistance to Casodex (bicalutamide) in prostate cancer cells in culture and xenograft models, via a switch of Casodex (bicalutamide) from androgen receptor antagonist to agonist (PMID: 16266977).",
            "molecularProfile": {
                "id": 7398,
                "profileName": "AR W742C"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3011,
                    "pubMedId": 16266977,
                    "title": "Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16266977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7398,
            "profileName": "AR W742C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 146272,
            "transcript": "NM_000044",
            "gDna": "chrX:g.67717530G>T",
            "cDna": "c.2226G>T",
            "protein": "p.W742C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}